SCHEMBL13367652

SCHEMBL13367652

Cc1ccc2c(c1)oc(=O)n2C(C)C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MIF P14174 3/20 0.50
CD74 P04233 1/20 0.40
PKM P14618 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
ASAH1 Q13510 1/20 0.39
HPGD P15428 2/20 0.39
NOS1 P29475 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
USP2 O75604 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PTGS2 P35354 2/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16141180 0.86 MIF (0.50) MIFCD74KMT2AMEN1POLB
SCHEMBL13340923 0.83 MEN1 (0.45) KMT2AMEN1POLBSMN1; SMN2
SCHEMBL13962146 0.81 GPR55 (0.42) MIFCD74PKMKMT2AMEN1
SCHEMBL13961728 0.81 SCN9A (0.34) MIFPKMKMT2AMEN1POLB
SCHEMBL14827511 0.81 MIF (0.41) MIFPKMKMT2AMEN1HPGD
SCHEMBL30349961 0.81 ALDH1A1 (0.39) MIFKMT2AMEN1HPGDSMN1; SMN2
SCHEMBL2600305 0.81 ALDH1A1 (0.39) MIFKMT2AMEN1HPGDSMN1; SMN2
SCHEMBL20251423 0.79 MIF (0.41) MIFPKMKMT2AMEN1L3MBTL1
SCHEMBL2600306 0.77 MAPK1 (0.52) MIFKMT2AMEN1POLBHPGD
SCHEMBL29591678 0.77 MAPK1 (0.52) MIFKMT2AMEN1POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224759-A1 INDANOL SUBSTITUTED DIAMINO PYRIMIDINE CARBOXAMIDES AS DUAL ATM/DNA-PK INHIBITORS BUGWORKS RESEARCH INDIA PVT. LTD (IN) 2025-10-30 WO disclosed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
US-20070265242-A1 Novel Carbapenem Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-11-15 US disclosed
US-20070265242-A1 Novel Carbapenem Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ MIF 4047/4885CD74 3972/4885PKM 81/4885
US-20070265242-A1 Novel Carbapenem Compound C1R, C3AR1, OXA1L MIF 3498/4885CD74 4518/4885PKM 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.